A prominent OL role in AMN pathogenesis is supported by the results of a gene-therapy study that used an adeno-associated vector (AAV) carrying the human ABCD1 gene driven by the myelin-associated glycoprotein (MAG) promoter [289]. Here, MAG is linked to adrenomyeloneuropathy.